Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

In The Star's annual year in review, the county's biggest business stories included housing proposals and the aftermath of a ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...

Abivax (ABVX) stock leads biotech M&A prospects for 2026 while Madrigal Pharmaceuticals (MDGL) trails, according to a survey ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

The new saw: Development-stage biotechs are maturing. Their drugs are winning approvals and independent commercial launches ...